Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS ...Middle East

CARLSBAD, Calif., April 5, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of a Phase 3 clinical trial of ION363 in patients with amyotrophic lateral sclerosis (ALS) with mutations in the fused in sarcoma gene (FUS). Patients with a mutation...

Read More Details
Finally We wish PressBee provided you with enough information of ( Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS )

Also on site :

• Grandpa of Idaho shooting suspect Wess Roley, 20, breaks his silence as chilling new details emerge about his past
• Apple claims San Jose engineer stole trade secrets, took them to rival
• Cruise Passengers Capture 'Miracle' Rescue After 2 Go Overboard: 'Tiny Dots Left Behind in a Massive Ocean'